ALNYAlnylam Pharmaceuticals, Inc.

ALNY Stock Price, Valuation & Chart | Alnylam Pharmaceuticals, Inc.

Compare

$231.83-2.20 (-0.94%)

At close · 16 Oct 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology

Overview Financials Dividends Ratios

ALNY Historical price chart

ALNY Key Stats

Market Capitalization31.02B

PE Ratio41.77

EPS5.55

Trading Volume1.40M

Today's High/Low237.91/231.25

Dividend Yield0.00

52 Week High/Low495.55/197.81

Shares Outstanding133.81M

ALNY Financial Statement

ALNY Analyst ratings

ALNY Analysis & performance metrics

ALNY Company profile

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.…

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed…

ALNY Management team

Name

Position

Kevin Joseph Fitzgerald Ph.D.

Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development

Timothy J. Maines

Chief Technical Operations & Quality Officer

Piyush Sharma J.D.

Chief Ethics & Compliance Officer

Jeffrey V. Poulton M.B.A.CFO

Chief Financial Officer & Executive Vice President

Robert W. Hesslein Esq., J.D.

Executive Vice President, Chief Legal Officer & Corporate Secretary

Christine Regan Lindenboom

Chief Corporate Communications Officer

Tolga Tanguler M.B.A.

Executive Vice President & Chief Commercial Officer

Phillip A. Sharp Ph.D.CTO

Co-Founder, Member of the Scientific Advisory Board & Independent Director

Name

Position

Kevin Joseph Fitzgerald Ph.D.

Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development

Timothy J. Maines

Chief Technical Operations & Quality Officer

Piyush Sharma J.D.

Chief Ethics & Compliance Officer

Jeffrey V. Poulton M.B.A.CFO

Chief Financial Officer & Executive Vice President

Robert W. Hesslein Esq., J.D.

Executive Vice President, Chief Legal Officer & Corporate Secretary

Christine Regan Lindenboom

Chief Corporate Communications Officer

Tolga Tanguler M.B.A.

Executive Vice President & Chief Commercial Officer

Phillip A. Sharp Ph.D.CTO

Co-Founder, Member of the Scientific Advisory Board & Independent Director

Management Team

Kevin Joseph Fitzgerald Ph.D.

Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development

Timothy J. Maines

Chief Technical Operations & Quality Officer

Piyush Sharma J.D.

Chief Ethics & Compliance Officer

Jeffrey V. Poulton M.B.A.CFO

Chief Financial Officer & Executive Vice President

Robert W. Hesslein Esq., J.D.

Executive Vice President, Chief Legal Officer & Corporate Secretary

Christine Regan Lindenboom

Chief Corporate Communications Officer

Tolga Tanguler M.B.A.

Executive Vice President & Chief Commercial Officer

Phillip A. Sharp Ph.D.CTO

Co-Founder, Member of the Scientific Advisory Board & Independent Director

Management

Kevin Joseph Fitzgerald Ph.D.

Executive Vice President, Chief Scientific Officer and Head of Early Research & Early Development

Timothy J. Maines

Chief Technical Operations & Quality Officer

Piyush Sharma J.D.

Chief Ethics & Compliance Officer

Jeffrey V. Poulton M.B.A.CFO

Chief Financial Officer & Executive Vice President

Robert W. Hesslein Esq., J.D.

Executive Vice President, Chief Legal Officer & Corporate Secretary

Christine Regan Lindenboom

Chief Corporate Communications Officer

Tolga Tanguler M.B.A.

Executive Vice President & Chief Commercial Officer

Phillip A. Sharp Ph.D.CTO

Co-Founder, Member of the Scientific Advisory Board & Independent Director

Total 8 executives

ALNY Frequently asked questions

What is Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price?

Current stock price of Alnylam Pharmaceuticals, Inc. (ALNY) stock is $231.83. The stock price is -0.94% lower in the session. The intraday range can be seen from this page. Volume of Alnylam Pharmaceuticals, Inc. (ALNY) stock is 1.40M.

Last updated at 16 Oct 2026, 08:00 pm.

Why is the Alnylam Pharmaceuticals, Inc. (ALNY) stock price going up or down today?

The stock price of Alnylam Pharmaceuticals, Inc. (ALNY) can change with earnings, company news, and overall market sentiment. Alnylam Pharmaceuticals, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Alnylam Pharmaceuticals, Inc. stock expensive at its current price?

Whether Alnylam Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ALNY on this page is 41.77. EPS on this page is 5.55. Compare those figures with peers and growth expectations before deciding if the current Alnylam Pharmaceuticals, Inc. price is justified.

How has the stock price of Alnylam Pharmaceuticals, Inc. (ALNY) performed historically?

Historical performance for Alnylam Pharmaceuticals, Inc. (ALNY) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ALNY reacted to past earnings and market events.

Should I buy Alnylam Pharmaceuticals, Inc. (ALNY) stock, at this price?

Buying Alnylam Pharmaceuticals, Inc. (ALNY) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.